Literature DB >> 16750217

Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.

Bao-cheng Huang1, Sandra Davern, Stephen J Kennel.   

Abstract

Phage display techniques identified a scFv, 15-9, which binds to murine laminin-1 and accumulated selectively in tumors. In this study, a covalent diabody was constructed by changing the amino acid residues at positions VH44 and VL100 to cysteine residues so that the diabody form could be stabilized via a disulfide bond. The covalent diabody was expressed in Pichia pastoris and purified by affinity chromatography. The binding properties were measured by surface plasmon resonance and solid phase binding of (125)I diabody and scFv. Data from the plasmon resonance method yielded calculated K(D)s of 4.4 x 10(-10) M for the covalent diabody and 9.9 x 10(-8) M for the scFv. K(D)s calculated from solid phase binding of radioiodinated proteins were 1.7-2.1 x 10(-10) M and 2.1-2.4 x 10(-8) M respectively. The rate of dissociation of (125)I scFv from solid phase laminin was independent of laminin concentration; however, the dissociation of the (125)I diabody was dependent both on the concentration of laminin and on the concentration of the diabody. Specifically, high concentrations of laminin yielded very slow rates of diabody dissociation indicating that bivalent attachments had formed. When higher amounts of diabody were used that essentially saturated the laminin sites with univalent binding, the dissociation rate was similar to that for the scFv indicating univalent binding. Biodistribution studies in tumor-bearing SCID mice showed that the covalent diabody improved the ratio of tumor/muscle 2 fold over that obtained with the scFv, although the absolute amount of protein bound to the tumor site was not significantly different for the two forms. The data also showed that retention of the diabody in the tumor and kidney, sites where laminin is present in high concentration, was much longer compared to that of scFv. These data are consistent with the hypothesis that both scFv and diabody forms bind to available laminin in vivo with similar association kinetics, but that in situations of high target concentration, the diabody can bind bivalently and is thus retained at the binding site much longer than the scFv.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750217     DOI: 10.1016/j.jim.2006.04.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Authors:  Sarah B Lloyd; Keith P Niven; Ben R Kiefel; David C Montefiori; Arnold Reynaldi; Miles P Davenport; Stephen J Kent; Wendy R Winnall
Journal:  Hum Vaccin Immunother       Date:  2017-09-26       Impact factor: 3.452

2.  Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin.

Authors:  Wen-Ling Chiu; Chi-Long Lin; Min-Hsiang Yang; Der-Lii M Tzou; Wen Chang
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

3.  Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity.

Authors:  Jian-Xin Zhao; Lian Yang; Zhen-Nan Gu; Hai-Qin Chen; Feng-Wei Tian; Yong-Quan Chen; Hao Zhang; Wei Chen
Journal:  Int J Mol Sci       Date:  2010-12-23       Impact factor: 5.923

4.  A unique bivalent binding and inhibition mechanism by the yatapoxvirus interleukin 18 binding protein.

Authors:  Brian Krumm; Xiangzhi Meng; Zhixin Wang; Yan Xiang; Junpeng Deng
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

5.  In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences.

Authors:  Angel M Cuesta; David Sánchez-Martín; Laura Sanz; Jaume Bonet; Marta Compte; Leonor Kremer; Francisco J Blanco; Baldomero Oliva; Luis Alvarez-Vallina
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.